191091-65-3

Upstream product

• 191092-15-6 (2R,4R)-4-benzyloxy-1-ethoxycarbonyl-2-[2-(p-toluenesulfonyloxy)ethyl]pyrrolidine 
• 318511-15-8 (2S,4R)-4-benzyloxy-1-ethoxycarbonyl-2-(ethoxycarbonylmethyl)pyrrolidine 
• 318511-16-9 (2R,4R)-4-benzyloxy-1-ethoxycarbonyl-2-(2-hydroxyethyl)pyrrolidine 
• 191091-64-2 (2R,4R)-4-Benzyloxy-2-(2-{2-[2-(2-methoxy-phenyl)-ethyl]-phenoxy}-ethyl)-pyrrolidine-1-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

[2-(O-Phenylalkyl)phenoxy]alkylamines III: Synthesis and selective serotonin-2 receptor binding (2).

A series of 12-(2-phenylethyl)phenoxy]ethylpyrrolidine derivatives were synthesized, and their affinity for serotonin-2 (5-HT2) and dopamine-2 (D2) receptors was examined. Among them, compound 17, (2R,4R)-4-hydroxy-2-[2-[2-[2-(3-methoxyphenyl)ethyl]phenoxylethyl] -1-methylpyrrolidine hydrochloride, showed high 5-HT2 receptor affinity in vitro. This compound was a more potent inhibitor of ex vivo 5-HT-induced platelet aggregation than compound 3, which was previously shown to be more potent than ketanserin (1) and sarpogrelate (2a). However, compound 17 produced gastric irritation in rats. Therefore, we carried out a further derivatization of 17, and compound 45 (R-102444), a lauryl ester prodrug of compound 17, was found to be a promising candidate as an antithrombotic agent. Oral administration of R-102444 produced a marked inhibition of 5-HT-induced ex vivo platelet aggregation, and R-102444 did not cause any gastric irritation. The antiaggregatory effects of R-102444 were more potent than those of sarpogrelate (2a) and its active metabolite, M-1 (2b). In addition, R-102444 exhibited more potent antithrombotic effects than sarpogrelate in a rat photochemically-induced thrombosis model.